ClinicalTrials.gg
WithdrawnNCT04968379Updated Jan 6, 2023

Safety, Tolerability, PK and PD of Intravenous Ferric Carboxymaltose in Infants With Iron Deficiency Anemia

A Phase 2 interventional study of Ferric carboxymaltose in Iron Deficiency, Anaemia, sponsored by American Regent, Inc.. Withdrawn at 4 sites in United States. Open to participants aged Up to 1 Year. Per ClinicalTrials.gov, last updated 2023-01-06.

Sponsored by American Regent, Inc. (part of Daiichi Sankyo) · Phase 2, Interventional, and Treatment

Why this study was withdrawn
Difficult to recruit and enroll patients for this study in a reasonable amount of time.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Non-randomized
Ages
Up to 1 Year
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 57 studies testing ferric carboxymaltose in Anemia, Iron-Deficiency — 7 open to participants now, 7 under way, none of them phase 3. ferric carboxymaltose · Anemia, Iron-Deficiency.

Enrollment
56th of 57
0 · median 100
Started
2022
with 1 other
Phase 2
8 of 57
none open now
Registered
42nd of 57
by date
Lead sponsor
11 of 57
American Regent, Inc.

Among the 57 studies testing ferric carboxymaltose in Anemia, Iron-Deficiency, this one is the 56th largest by enrollment, is one of 2 that started in 2022, is one of 8 in phase 2, and was the 42nd registered.

Anemia, Iron-Deficiency

601 studies on the registry are indexed under Anemia, Iron-Deficiency; 96 are open to participants now.

Browse Anemia, Iron-Deficiency studies →

Open to participants now

7 of the 57 studies testing ferric carboxymaltose in Anemia, Iron-Deficiency are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About ferric carboxymaltose

ferric carboxymaltose: first FDA approval 2013 (INJECTAFER). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Anemia, Iron-Deficiency studies recruiting now, 19 (35%) set no upper age limit and 32 (58%) stop at 75 or younger; 16 take children under 18; 17 take healthy volunteers.

This study: Up to 1 Year · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies testing ferric carboxymaltose in Anemia, Iron-Deficiency, or all of them as a file.
02

Study summary

An Open-Label, Multi-Center Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous Ferric Carboxymaltose (FCM) in Infants (0-1 year) with Iron Deficiency Anemia.

Read the detailed description

A phase II, open-label, multi-center study with 2 Cohorts to evaluate the safety, tolerance, PK, and PD profile of intravenous (IV) FCM in infants 0 to 1 year of age with IDA after receiving either a 5.0 mg/kg or 7.5 mg/kg dose of FCM.

Participants will have a screening evaluation within 14 days of the first dose of study drug. A medically supervised environment is required on Day 1 (day of dosing) and for 4 hours post dosing. Participants are allowed to be enrolled if satisfying the inclusion and exclusion criteria. Participants will return to the study site for additional evaluation and sampling on Days 8 (± 2 days), 15 (± 2 days), 22 (± 2 days), and 36 (± 2 days).

03

Conditions studied

  • Iron Deficiency, Anaemia
04

Who can participate

Ages eligible
Up to 1 Year
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female participants 0 to 1 year of age, medically indicated for iron replacement, with his/her parent or legal guardian willing and able to sign the form approved by the IRB / Independent Ethics Committee (IEC).
  2. Screening ≥7 g/dL to \<10 g/dL.
  3. Infants with any of the following conditions:

    • Heart failure with IDA defined as syndromes of excessive preload, excessive afterload, abnormal rhythm, or decreased contractility
    • Gastrointestinal diseases with acquired short bowel syndrome (due to volvulus, necrotizing enterocolitis from surgical resection or spontaneous intestinal perforation)
    • Gastrointestinal intolerance of oral iron or an unsatisfactory response to oral iron
    • Other conditions associated with IDA which in the opinion of the investigator might benefit from administration of FCM

Exclusion criteria

Exclusion Criteria:

  1. Known history of reaction to FCM.
  2. Body weight \<2.5 kg.
  3. History of acquired iron overload, hemochromatosis, or other iron accumulation disorders.
  4. Hemodialysis-dependent chronic kidney disease.
  5. History of significant diseases of the liver, hematopoietic system, cardiovascular system, or other conditions which, on the opinion of the investigator, may place a participant at added risk for participation in the study.
  6. Active infection.
  7. Anemia due to reasons other than iron deficiency (e.g., hemoglobinopathy vitamin B12 deficiency, or folic acid deficiency).
  8. Blood transfusion in the 4 weeks prior to consent.
  9. Administration of an iron-containing product within 14 days of administration of the study article.
  10. Administration and / or use of an product (drug or device) within 30 days of screening.
  11. Current participation in another clinical trial.
  12. Unable to comply with study procedures and assessments.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Ferric Carboxymaltose

    To evaluate the safety, tolerance, PK and PD profile of intravenous (IV) FCM in infants 0 to 1 year of age with IDA after receiving a 5.0 mg/kg dose of FCM

    Drug: Ferric carboxymaltose

  • Experimental
    Injectafer

    To evaluate the safety, tolerance, PK and PD profile of intravenous (IV) FCM in infants 0 to 1 year of age with IDA after receiving a 7.5 mg/kg dose dose of FCM.

    Drug: Ferric carboxymaltose

Interventions

06

What researchers measure

Primary outcomes

  1. Treatment-emergent adverse events

    Treatment-emergent clinical laboratory test (clinical chemistry and hematology) abnormalities

    Time frame: Baseline to Day 36

  2. Change in hemoglobin (Hb): g/dL

    determine appropriate dosing of FCM in infants from 0 to 1 year of age by evaluating PD parameters

    Time frame: baseline to Days 8, 15, 22, and 36

  3. Change in reticulocytes count: %

    determine appropriate dosing of FCM in infants from 0 to 1 year of age by evaluating PD parameters

    Time frame: baseline to Days 8, 15, 22, and 36

  4. Evaluate the PD parameters - Change in serum iron: mcg/dL

    To determine appropriate dosing of FCM in infants from 0 to 1 year of age by evaluating PD parameters.

    Time frame: baseline to Day 36

  5. Evaluate the PD parameters - Change in serum ferritin: ng/mL

    Description: To determine appropriate dosing of FCM in infants from 0 to 1 year of age by evaluating PD parameters.

    Time frame: baseline to Day 36

  6. Evaluate the PD parameters - Change in total iron binding capacity [TIBC]): mcg/dL

    Description: To determine appropriate dosing of FCM in infants from 0 to 1 year of age by evaluating PD parameters.

    Time frame: baseline to Day 36

  7. Evaluate the PD parameters - Change in serum transferrin saturation [TSAT]): mg/dL

    Description: To determine appropriate dosing of FCM in infants from 0 to 1 year of age by evaluating PD parameters.

    Time frame: baseline to Day 36

07

Study locations

4 sites
  • University of Iowa
    Iowa City, Iowa 52242, United States
  • Cohen Children's Medical Center
    New Hyde Park, New York 11040, United States
  • Nationwide Children's Hospital
    Columbus, Ohio 43205, United States
  • St. Christopher's Hospital for Children
    Philadelphia, Pennsylvania 19134, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2022 (actual). Primary completion is estimated for Oct 2024, 26 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2020
First posted
Jul 20, 2021
StartActual
Jul 21, 2022
Primary completionEst.
Oct 8, 2024
CompletionEst.
Dec 12, 2024
Last update
Jan 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04968379
Responsible party
Sponsor
First posted
Jul 20, 2021
Start date
Jul 21, 2022
Primary completion
Oct 8, 2024 (estimated)
Completion
Dec 12, 2024 (estimated)
Last update
Jan 6, 2023

Study contacts

Mark Falone, MD
study director · American Regent

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ferric carboxymaltose

Start the discussion